Why Soleno Therapeutics Stock Rocketed Higher on Monday [Yahoo! Finance]
Neurocrine Biosciences, Inc. (NBIX)
Last neurocrine biosciences, inc. earnings: 2/4 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
neurocrine.com/about-us/webcasts-presentations
Company Research
Source: Yahoo! Finance
This left the commercial-stage biotech with a juicy 32% gain on the day's trading session. Biotech buyout That morning, Soleno and its peer biotech Neurocrine Biosciences (NASDAQ: NBIX) , announced that they had signed a definitive agreement under which Neurocrine would acquire Soleno. The deal, valued at $2.9 billion, will see Neurocrine pay $53 per share in an all-cash transaction to own Soleno. Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue » Image source: Getty Images. Soleno is a rare-disease specialist who earned its first approval from the Food and Drug Administration (FDA) in March 2025. This nod was for Vykat XR, a medicine that treats hyperphagia (excessive hunger) arising from the genetic disorder Prader-Willi Syndrome. In their joint press release on the acquisition, the two companies quoted N
Show less
Read more
Impact Snapshot
Event Time:
NBIX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NBIX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NBIX alerts
High impacting Neurocrine Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
NBIX
News
- Stock Market Today, April 6: Soleno Therapeutics Climbs After $2.9 Billion All-Cash Buyout Agreement [Globe and Mail, The (Toronto, Canada)]Globe and Mail, The
- Neurocrine Biosciences (NBIX) had its "buy" rating reaffirmed by Needham & Company LLC. They now have a $185.00 price target on the stock.MarketBeat
- Neurocrine Biosciences Details $2.9B Soleno Buyout, Touts Vykat XR as Potential Blockbuster [Yahoo! Finance]Yahoo! Finance
- Neurocrine Biosciences, Inc. (NBIX) M&A Call Transcript [Seeking Alpha]Seeking Alpha
- Neurocrine to acquire Prader-Will drug in $2.9B Soleno buyout [Yahoo! Finance]Yahoo! Finance
NBIX
Earnings
- 2/11/26 - Beat
NBIX
Sec Filings
- 4/6/26 - Form 8-K
- 3/27/26 - Form SCHEDULE
- 3/17/26 - Form 3
- NBIX's page on the SEC website